BioMarin Pharmaceutical I... (BMRN)
BioMarin Pharmaceutical Statistics
Share Statistics
BioMarin Pharmaceutical has 190.78M shares outstanding. The number of shares has increased by 0.47% in one year.
| Shares Outstanding | 190.78M |
| Shares Change (YoY) | 0.47% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 96.12% |
| Shares Floating | 188.29M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.38M, so 2.3% of the outstanding shares have been sold short.
| Short Interest | 4.38M |
| Short % of Shares Out | 2.3% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 3.14 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is 15.23. BioMarin Pharmaceutical's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | 15.23 |
| PS Ratio | 4.38 |
| Forward PS | 3.3 |
| PB Ratio | 2.21 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
BioMarin Pharmaceutical Inc. has an Enterprise Value (EV) of 18.49B.
| EV / Earnings | 43.32 |
| EV / Sales | 6.48 |
| EV / EBITDA | 28.42 |
| EV / EBIT | 38.18 |
| EV / FCF | 38.89 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of undefined.
| Current Ratio | 5.33 |
| Quick Ratio | 3.29 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | 9.63 |
| Cash Flow / Debt | 0.95 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is 0.08% and return on capital (ROIC) is 6.09%.
| Return on Equity (ROE) | 0.08% |
| Return on Assets (ROA) | 0.06% |
| Return on Capital (ROIC) | 6.09% |
| Revenue Per Employee | $938,787.83 |
| Profits Per Employee | $140,414.14 |
| Employee Count | 3,040 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.47 |
Taxes
| Income Tax | 114.9M |
| Effective Tax Rate | 0.21 |
Stock Price Statistics
The stock price has increased by -18.81% in the last 52 weeks. The beta is 0.33, so BioMarin Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -18.81% |
| 50-Day Moving Average | 67.58 |
| 200-Day Moving Average | 73.42 |
| Relative Strength Index (RSI) | 51.93 |
| Average Volume (20 Days) | 1.56M |
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.13.
| Revenue | 2.85B |
| Gross Profit | 2.27B |
| Operating Income | 484.21M |
| Net Income | 426.86M |
| EBITDA | 650.53M |
| EBIT | 484.21M |
| Earnings Per Share (EPS) | 2.13 |
Balance Sheet
The company has 942.84M in cash and 602.71M in debt, giving a net cash position of 340.13M.
| Cash & Cash Equivalents | 942.84M |
| Total Debt | 602.71M |
| Net Cash | 340.13M |
| Retained Earnings | -194.69M |
| Total Assets | 6.99B |
| Working Capital | 2.63B |
Cash Flow
In the last 12 months, operating cash flow was 572.84M and capital expenditures -85.42M, giving a free cash flow of 475.42M.
| Operating Cash Flow | 572.84M |
| Capital Expenditures | -85.42M |
| Free Cash Flow | 475.42M |
| FCF Per Share | 2.5 |
Margins
Gross margin is 79.67%, with operating and profit margins of 16.97% and 14.96%.
| Gross Margin | 79.67% |
| Operating Margin | 16.97% |
| Pretax Margin | 18.98% |
| Profit Margin | 14.96% |
| EBITDA Margin | 22.79% |
| EBIT Margin | 16.97% |
| FCF Margin | 16.66% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.01% |
| FCF Yield | 3.52% |
Analyst Forecast
The average price target for BMRN is $90, which is 27.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $90 |
| Price Target Difference | 27.3% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
Scores
| Altman Z-Score | 7.23 |
| Piotroski F-Score | 6 |